Five-year Antibody Persistence and Safety Following a Booster Dose of Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine.
Tejedor, Juan Carlos MD *; Merino, Jose Manuel MD +; Moro, Manuel MD ++; Navarro, Maria-Luisa MD [S]; Espin, Jose MD [P]; Omenaca, Felix MD [forms double vertical]; Garcia-Sicilia, Jose MD [forms double vertical]; Moreno-Perez, David MD **; Ruiz-Contreras, Jesus MD ++; Centeno, Fernando MD ++++; Barrio, Francisco MD [S][S]; Cabanillas, Lucia MD [P][P]; Muro, Marta MD [P][P]; Esporrin, Carlos MD [forms double vertical][forms double vertical]; De Torres, Maria Jose MD [S][S]; Caubet, Magalie MA ***; Boutriau, Dominique MD ***; Miller, Jacqueline M. MD +++; Mesaros, Narcisa MD ***
Pediatric Infectious Disease Journal.
31(10):1074-1077, October 2012.
(Format: HTML, PDF)
Background: Booster vaccination with the combined Haemophilus influenza type b-Neisseria meningitides serogroup C-tetanus toxoid vaccine (Hib-MenC-TT) has been reported to induce different MenC antibody responses depending on the priming vaccines, with a possible impact on long-term protection. Here, the five-year persistence of immune responses induced by a booster dose of Hib-MenC-TT was evaluated in toddlers primed with either Hib-MenC-TT or MenC-TT.
Methods: This is the follow-up of a phase III, open, randomized study, in which a Hib-MenC-TT booster dose was given at 13.14 months of age to toddlers primed with either 3 doses of Hib-MenC-TT or 2 doses of MenC-TT in infancy. Children in the control group had received 3 primary doses and a booster dose of MenC-CRM197. Functional antibodies against MenC were measured by a serum bactericidal assay with rabbit complement (rSBA-MenC) and antibodies against Hib polyribosylribitol phosphate by enzyme-linked immunosorbent assay. Serious adverse events considered by the investigator to be possibly related to vaccination were to be reported throughout the study.
Results: At 66 months postbooster, rSBA-MenC titers >=8 were retained by 82.6% of children primed with Hib-MenC-TT, 94.1% of children primed with MenC-TT, and 60.9% of children in the control group. All children who received the Hib-MenC-TT booster dose retained anti- polyribosylribitol phosphate concentrations >=0.15 [mu]g/mL. No serious adverse events considered possibly related to vaccination were reported.
(C) 2012 Lippincott Williams & Wilkins, Inc.